Program

The 1.5 day course consists of 10 invited lectures with ample time for Q&A, and breakout sessions. The preliminary agenda is as follows. The program is subject to change. Please stay tuned with us.

Download a pdf version of the program.

7 November
8:00 AMRegistration & Welcome coffee
8.20 AMOpening, introduction and pre-test
8.30 AMThe clinical and economic importance of optimizing dose
Mark Ratain, The University of Chicago
9.30 AMPlacing preclinical drug metabolism and pharmacokinetic data in context
Magnus Ingelman-Sundberg, Karolinska Institutet
10:30 AMCoffee break
11.00 AMRedefining the primary objective of phase 1 trials
Ruth Plummer, Newcastle University
12.00 PMClinical endpoints useful for guiding early clinical development
Jaap Verweij, Erasmus Medical Centre
1.00 PMLunch & Breakout session slots
2.00 PMPharmacometrics for the non-pharmacometrician
Lena Friberg, Uppsala University
3.00 PMUsing genetic and pharmacokinetic data from early clinical trials to guide subsequent clinical development
Magnus Ingelman-Sundberg, Karolinska Institutet
4.00 PMCoffee break
4.30 PMOptimizing the use of pharmacodynamic biomarkers
Mark Ratain, The University of Chicago
5:30 PMEnd of Day 1
6.00 PMNetworking dinner (optional)
8 November
8.00 AMBreakfast & Breakout session slots
9.00 AMTrial designs for the development of combinations of an investigational drug and a marketed drug
Jaap Verweij, Erasmus Medical Centre
10.00 AMSpecial challenges for the development of immunotherapy drugs and combinations
Ruth Plummer, Newcastle University
11:00 AMCoffee break
11.30 AMUse of clinical trial simulation in oncology drug development
Lena Friberg, Uppsala University
12:30 PMPost-test and Closure of the course

 

FACULTY